RECURRENT HIGH GRADE GLIOMA
Clinical trials for RECURRENT HIGH GRADE GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HIGH GRADE GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT HIGH GRADE GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Brain cancer patients get virus injection in new hope trial
Disease control ENROLLING_BY_INVITATIONThis study tests a new treatment for people with recurrent high-grade glioma, a serious brain cancer that has come back after standard therapy. The treatment uses a modified virus (oncolytic adenovirus) designed to infect and kill cancer cells while also boosting the immune syste…
Matched conditions: RECURRENT HIGH GRADE GLIOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Bio-Targeting Therapeutics Technology Co., Ltd • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
RNA vaccine shows promise in fight against childhood cancers
Disease control OngoingThis study tests a new RNA vaccine for children and young adults (ages 3-25) with recurrent high-grade glioma or osteosarcoma that has spread to the lungs. The vaccine aims to train the immune system to attack cancer cells. The trial will check safety, the right dose, and whether…
Matched conditions: RECURRENT HIGH GRADE GLIOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated May 26, 2026 05:46 UTC
-
Stem cell and immunotherapy combo tested in kids with returning brain tumors
Disease control OngoingThis early-phase trial tests whether giving children with recurrent high-grade glioma a special type of stem cell treatment along with the immunotherapy drug nivolumab is safe and possible. The study involves 12 children whose brain tumors have come back after standard treatments…
Matched conditions: RECURRENT HIGH GRADE GLIOMA
Phase: PHASE1 • Sponsor: University of Florida • Aim: Disease control
Last updated May 22, 2026 14:02 UTC